A recent decision of the Federal Court, GlaxoSmithKline v. Apotex, confirms that, even under the post-1989 provisions of the Patent Act (the "Act"), patents that issue from voluntary divisional applications are susceptible to attacks of invalidity on the ground of double patenting.